Clinical Research · global
Oral psoriasis drug icotrokinra adds two-year evidence: over 70% of patients achieve 90% improvement in skin lesions
A key test of psoriasis treatment is how long skin improvement lasts. ICONIC-LEAD follow-up through week 112 shows sustained response rates with the oral IL-23 receptor peptide therapy, but long-term adverse event rates and adolescent subgroup results have yet to be fully disclosed.
For patients with plaque psoriasis, the resolution of redness and scaling is just one step in treatment; years of disease control lie ahead. On October 9, Johnson & Johnson announced new results from the phase 3 ICONIC-LEAD trial of the oral drug icotrokinra: skin clearance and itch improvement remained stable through week 112, adding evidence of the therapy’s long-term effects. The data were presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas.
Icotrokinra is an oral peptide that blocks the interleukin-23 (IL-23) receptor, thereby inhibiting inflammatory signals associated with psoriasis. ICONIC-LEAD enrolled 684 patients aged 12 years and older with moderate-to-severe plaque psoriasis, including 66 adolescents. According to the trial design summarized by *Contemporary Pediatrics*, participants were initially randomized to receive icotrokinra 200 mg daily or placebo; after week 16, the placebo group switched to icotrokinra, so the two-year results do not provide evidence from an ongoing comparison with placebo.
From week 64 through week 112, at least 72% of patients treated with icotrokinra achieved PASI 90. PASI is an index that combines the extent of skin lesions with the severity of redness, thickness, and scaling; PASI 90 represents an improvement of at least 90% from baseline. Over the same period, at least 44% achieved PASI 100, meaning complete clearance of skin lesions as assessed by this index. These figures describe response rates during follow-up and cannot be directly interpreted to mean that every patient who met the threshold experienced no fluctuations.
Another investigator-assessed measure, IGA, showed a similar trend: at least 70% of patients achieved clear or almost clear skin, and at least 46% achieved completely clear skin. HCPLive also reported that 78% of patients maintained clinically meaningful itch improvement from weeks 64 through 112. Beyond skin lesion scores, this patient-reported outcome adds a perspective on how symptoms feel, but the announcement did not specify the threshold for itch improvement or the number of patients included in the analysis.
The trial also examined whether patients could regain a response after treatment interruption. Among patients who had achieved PASI 90 at week 24 and subsequently had icotrokinra withdrawn, 85% achieved PASI 90 again within 24 weeks of restarting treatment. This helps clarify the potential effects of retreatment, but is insufficient to establish a routine treatment discontinuation strategy. HCPLive noted that the company did not disclose complete withdrawal and retreatment results for PASI 75 and IGA 0/1 responders in the announcement.
On safety, Johnson & Johnson said that no new safety signals were identified through week 112 and that the results were consistent with existing safety data. However, *Dermatology Times* noted that the announcement did not provide adverse event rates. Without data on event frequency, severity, and treatment discontinuation due to side effects, it remains difficult to fully assess the risks of long-term treatment; “no new signals” also does not mean there are no side effects.
The main value of this update is that it extends efficacy observations beyond two years, providing more evidence for the durability of oral IL-23 receptor therapy. Several limitations still need to be kept in mind when interpreting the findings: the announcement did not fully explain the denominators used in the long-term analyses, how patients who withdrew from the trial and missing data were handled, or present adolescent results separately. Reports from multiple media outlets were primarily based on the same company announcement and conference materials; comparing the long-term performance of other treatments still requires complete study data and direct comparative evidence.